RS52885B - Niskofrekventna terapija glatiramer acetatom - Google Patents

Niskofrekventna terapija glatiramer acetatom

Info

Publication number
RS52885B
RS52885B RS20130293A RSP20130293A RS52885B RS 52885 B RS52885 B RS 52885B RS 20130293 A RS20130293 A RS 20130293A RS P20130293 A RSP20130293 A RS P20130293A RS 52885 B RS52885 B RS 52885B
Authority
RS
Serbia
Prior art keywords
patient
glatiramer acetate
use according
treatment
multiple sclerosis
Prior art date
Application number
RS20130293A
Other languages
English (en)
Serbian (sr)
Inventor
Ety Klinger
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43605835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52885(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of RS52885B publication Critical patent/RS52885B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
RS20130293A 2009-08-20 2010-08-19 Niskofrekventna terapija glatiramer acetatom RS52885B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27468709P 2009-08-20 2009-08-20
US33761210P 2010-02-11 2010-02-11
PCT/US2010/002283 WO2011022063A1 (en) 2009-08-20 2010-08-19 Low frequency glatiramer acetate therapy

Publications (1)

Publication Number Publication Date
RS52885B true RS52885B (sr) 2014-02-28

Family

ID=43605835

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20130293A RS52885B (sr) 2009-08-20 2010-08-19 Niskofrekventna terapija glatiramer acetatom
RS20170053A RS55607B1 (sr) 2009-08-20 2010-08-19 Niskofrekventna terapija glatiramer acetatom

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20170053A RS55607B1 (sr) 2009-08-20 2010-08-19 Niskofrekventna terapija glatiramer acetatom

Country Status (34)

Country Link
US (15) US8399413B2 (enExample)
EP (5) EP2405749B1 (enExample)
JP (3) JP6038653B2 (enExample)
KR (4) KR20170123354A (enExample)
CN (3) CN107050423A (enExample)
AR (2) AR077896A1 (enExample)
AT (1) AT15421U1 (enExample)
AU (1) AU2010284666B2 (enExample)
BR (1) BR112012003730A2 (enExample)
CA (2) CA2760802C (enExample)
CY (2) CY1114537T1 (enExample)
CZ (2) CZ30474U1 (enExample)
DE (1) DE202010018377U1 (enExample)
DK (5) DK2405749T3 (enExample)
EA (3) EA032287B1 (enExample)
ES (4) ES2689711T3 (enExample)
HK (2) HK1258008A1 (enExample)
HR (4) HRP20130677T1 (enExample)
HU (2) HUE031282T2 (enExample)
IL (3) IL218106A0 (enExample)
LT (3) LT3199172T (enExample)
ME (2) ME01536B (enExample)
MX (1) MX2012002082A (enExample)
NZ (1) NZ598661A (enExample)
PL (4) PL2630962T3 (enExample)
PT (4) PT3199172T (enExample)
RS (2) RS52885B (enExample)
SG (2) SG178495A1 (enExample)
SI (4) SI2405749T1 (enExample)
SK (1) SK501352015U1 (enExample)
SM (2) SMT201700057T1 (enExample)
TW (3) TWI643614B (enExample)
UA (1) UA103699C2 (enExample)
WO (1) WO2011022063A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US8077333B2 (en) * 2002-09-09 2011-12-13 Canon Kabushiki Kaisha Printing control apparatus and printing control method
PL2630962T3 (pl) * 2009-08-20 2018-12-31 Yeda Research & Development Company, Ltd. Terapia octanem glatirameru podawanym z niewielką częstością
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
JP2014530819A (ja) 2011-10-10 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド 酢酸グラチラマーに対する臨床的応答性を予測するために有用な一塩基多形
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
KR20150111945A (ko) * 2013-01-04 2015-10-06 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트 관련 완제의 특성조사
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN103641897B (zh) * 2013-11-27 2017-01-04 深圳翰宇药业股份有限公司 一种合成醋酸格拉替雷的方法
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
WO2015195605A1 (en) * 2014-06-17 2015-12-23 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of glatiramer acetate by oral patches
CN104844697B (zh) * 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN107550853B (zh) * 2016-06-30 2020-06-12 深圳翰宇药业股份有限公司 一种醋酸格拉替雷注射液的制备方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
JP7193448B2 (ja) 2016-08-31 2022-12-20 マピ ファーマ リミテッド 酢酸グラチラマーを含むデポシステム
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
WO2019036363A1 (en) 2017-08-14 2019-02-21 Progenity Inc. TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
KR102519053B1 (ko) 2021-02-08 2023-04-06 건국대학교 산학협력단 염산가스의 농도 측정을 위한 수분 전처리 시스템
KR102519054B1 (ko) 2021-03-12 2023-04-06 건국대학교 산학협력단 나피온 드라이어와 수분 전처리장치의 결합시스템
WO2023062511A1 (en) * 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
CA3220684A1 (en) 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
EP0219899B1 (en) 1985-10-11 1990-08-08 Duphar International Research B.V Automatic injector
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
US6454746B1 (en) 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
CA2336238A1 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1115743B1 (en) 1998-09-25 2009-05-13 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en) 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
CA2355400A1 (en) 1998-11-12 2000-05-18 Yeda Research And Development Co., Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
HU231064B1 (hu) 1999-08-27 2020-03-30 Genentech, Inc. Anti-ErbB2 antitestek adagolási sémái és alkalmazásuk rákos betegségek kezelésére
DE60112718T2 (de) 2000-01-20 2006-06-29 Yeda Research And Development Co., Ltd. Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
IL150895A0 (en) 2000-02-18 2003-02-12 Teva Pharma Oral, nasal and pulmonary formulations of copolymer-1
HUP0302333A3 (en) 2000-06-05 2005-07-28 Teva Pharma The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
NZ520282A (en) 2000-06-07 2004-09-24 Yeda Res & Dev The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
ES2349033T3 (es) 2001-12-04 2010-12-22 Teva Pharmaceutical Industries, Ltd. Procedimientos para la medida de la actividad del acetato de glatiramer.
AU2003283152A1 (en) 2002-11-13 2004-06-03 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
JP2006507061A (ja) 2002-11-25 2006-03-02 テクファーマ・ライセンシング・アクチェンゲゼルシャフト リセット可能な解放安全装置を有する自動注射装置
US7274347B2 (en) 2003-06-27 2007-09-25 Texas Instruments Incorporated Prevention of charge accumulation in micromirror devices through bias inversion
CA2513567C (en) 2003-01-21 2012-10-23 Yeda Research And Development Co. Ltd. Cop 1 for treatment of inflammatory bowel diseases
WO2004091573A1 (en) 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
US7968511B2 (en) 2003-05-14 2011-06-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
EA200600877A1 (ru) 2003-10-31 2006-12-29 Тева Фармасьютикал Индастриз, Лтд. Наночастицы для доставки лекарств
HUP0303779A2 (en) * 2003-11-20 2006-02-28 Richter Gedeon Vegyeszet Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
JP2007535498A (ja) 2004-03-03 2007-12-06 テバ ファーマシューティカル インダストリーズ リミティド グラチラマー・アセテートおよびリルゾールでの併用療法
WO2005092066A2 (en) * 2004-03-25 2005-10-06 Janssen Pharmaceutica N.V. Imidazole compounds
AU2005244814B2 (en) 2004-05-07 2011-09-15 Ares Trading S.A. Methods of treating disease with random copolymers
US20060194725A1 (en) 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
JP5274011B2 (ja) * 2004-06-25 2013-08-28 アイディー バイオメディカル コーポレイション オブ ケベック 神経障害を治療するための組成物および方法
EP1796710A4 (en) 2004-09-02 2010-05-26 Teva Pharma THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
US7560100B2 (en) 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
ZA200702591B (en) 2004-09-09 2009-03-25 Teva Pharma Process for preparation of mixtures of polypeptides using purified hydrobromic acid
CA2583589C (en) 2004-10-29 2012-04-24 Sandoz Ag Processes for preparing glatiramer
BRPI0606301A2 (pt) 2005-02-02 2009-07-07 Teva Pharma processo para fabricar uma mistura de sais de acetato de polipeptìdeos, processo para fabricar uma mistura de sais de polipeptìdeos de trifluoroacetila não protegidos, mistura de sais de acetato de polipeptìdeos, composição farmacêutica, processos para a preparação de uma composição farmacêutica, e, mistura de polipeptìdeos de trifluoroacetila protegidos
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
DK1848415T3 (da) 2005-02-17 2013-07-08 Teva Pharma Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose
EP1891233A4 (en) 2005-04-25 2010-03-24 Yeda Res & Dev MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
WO2007030573A2 (en) 2005-09-09 2007-03-15 Yeda Research And Development Co. Ltd. Polypeptides useful for molecular weight determinations
US20070161566A1 (en) * 2006-01-11 2007-07-12 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
SG173339A1 (en) 2006-06-30 2011-08-29 Abbott Biotech Ltd Automatic injection device
CN101511862A (zh) 2006-07-05 2009-08-19 莫门塔制药股份有限公司 制备共聚物-1的改进方法
US20110123482A1 (en) * 2007-10-01 2011-05-26 The Johns Hopkins University Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide
EA201070656A1 (ru) * 2007-11-28 2010-12-30 Тева Фармасьютикал Индастриз, Лтд. Способ задержки начала проявления клинически определенного рассеянного склероза
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US20110060279A1 (en) 2009-07-15 2011-03-10 Ayelet Altman Reduced Volume Formulation of Glatiramer Acetate and Methods of Administration
PL2630962T3 (pl) 2009-08-20 2018-12-31 Yeda Research & Development Company, Ltd. Terapia octanem glatirameru podawanym z niewielką częstością
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
JP2014530819A (ja) 2011-10-10 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド 酢酸グラチラマーに対する臨床的応答性を予測するために有用な一塩基多形
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
KR20150111945A (ko) 2013-01-04 2015-10-06 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트 관련 완제의 특성조사
JP2016512552A (ja) 2013-03-12 2016-04-28 テバ ファーマシューティカル インダストリーズ リミティド リツキシマブ導入療法とその後の酢酸グラチラマー療法

Also Published As

Publication number Publication date
CY1114537T1 (el) 2016-10-05
TWI477273B (zh) 2015-03-21
US20190054013A1 (en) 2019-02-21
US20110046065A1 (en) 2011-02-24
CN102625657A (zh) 2012-08-01
DK2630962T3 (en) 2018-07-23
HK1165959A1 (en) 2012-10-19
EA201691347A3 (ru) 2016-11-30
US20180311149A1 (en) 2018-11-01
ES2689711T3 (es) 2018-11-15
AU2010284666B2 (en) 2012-12-06
SI2630962T1 (sl) 2018-10-30
WO2011022063A1 (en) 2011-02-24
EA201400394A1 (ru) 2014-10-30
SMT201700057T1 (it) 2017-03-08
KR20140061559A (ko) 2014-05-21
CA2760802A1 (en) 2011-02-24
PL3199172T3 (pl) 2019-01-31
PL2949335T3 (pl) 2017-07-31
IL233468A0 (en) 2014-08-31
EA201270292A1 (ru) 2012-12-28
PL2405749T3 (pl) 2013-12-31
EA019998B1 (ru) 2014-07-30
TW201119645A (en) 2011-06-16
IL218106A0 (en) 2012-04-30
LT2630962T (lt) 2018-10-25
DE202010018377U1 (de) 2016-02-25
AT15421U1 (de) 2017-08-15
ES2612001T4 (es) 2018-02-07
AR077896A1 (es) 2011-09-28
DK201600003U1 (da) 2016-01-22
SMT201700057B (it) 2017-03-08
PT3199172T (pt) 2018-10-18
US20150250845A1 (en) 2015-09-10
EP2630962A1 (en) 2013-08-28
HRP20181253T1 (hr) 2018-11-02
CA2760802F (en) 2011-02-24
LT3199172T (lt) 2018-10-25
PL2630962T3 (pl) 2018-12-31
ES2612001T3 (es) 2017-05-11
AU2010284666A1 (en) 2011-09-22
EP2630962B1 (en) 2018-06-27
EA032283B1 (ru) 2019-05-31
SG10201405806SA (en) 2014-11-27
PT2630962T (pt) 2018-08-01
TW201521718A (zh) 2015-06-16
TWI643614B (zh) 2018-12-11
HUE031282T2 (hu) 2017-06-28
US20130165387A1 (en) 2013-06-27
US20120071416A1 (en) 2012-03-22
CY1118529T1 (el) 2017-07-12
EP2405749B1 (en) 2013-05-08
MX2012002082A (es) 2012-08-23
CA2876966A1 (en) 2011-02-24
EP3199172A1 (en) 2017-08-02
HRP20181254T1 (hr) 2019-01-25
ES2688873T3 (es) 2018-11-07
ES2424692T3 (es) 2013-10-07
KR20160038057A (ko) 2016-04-06
HK1218250A1 (en) 2017-02-10
US9402874B2 (en) 2016-08-02
EA019998B9 (ru) 2016-01-29
AR099078A2 (es) 2016-06-29
HK1225310A1 (zh) 2017-09-08
US8399413B2 (en) 2013-03-19
HUE039335T2 (hu) 2018-12-28
SI2405749T1 (sl) 2013-10-30
SG178495A1 (en) 2012-03-29
TW201733575A (zh) 2017-10-01
UA103699C2 (ru) 2013-11-11
SI3199172T1 (sl) 2018-10-30
CA2760802C (en) 2016-01-12
EA201691347A2 (ru) 2016-10-31
US20150202247A1 (en) 2015-07-23
PT2405749E (pt) 2013-07-22
US20180064639A1 (en) 2018-03-08
CN107050423A (zh) 2017-08-18
NZ598661A (en) 2013-02-22
US20170296464A1 (en) 2017-10-19
EA032287B1 (ru) 2019-05-31
HRP20170056T2 (hr) 2017-12-15
ME01536B (me) 2014-04-20
JP2013502415A (ja) 2013-01-24
US20170196803A1 (en) 2017-07-13
HRP20130677T1 (en) 2013-10-11
US20190175494A1 (en) 2019-06-13
US20170095523A1 (en) 2017-04-06
JP6038653B2 (ja) 2016-12-07
HK1258008A1 (en) 2019-11-01
US20150164977A1 (en) 2015-06-18
CN105770855A (zh) 2016-07-20
US20160250251A1 (en) 2016-09-01
DK2405749T3 (da) 2013-07-15
EP3409286A1 (en) 2018-12-05
KR20170123354A (ko) 2017-11-07
BR112012003730A2 (pt) 2020-07-21
JP2015187125A (ja) 2015-10-29
EP3199172A8 (en) 2017-10-11
EP2405749A4 (en) 2012-08-22
JP2017132773A (ja) 2017-08-03
US9155776B2 (en) 2015-10-13
US8232250B2 (en) 2012-07-31
DK2949335T3 (en) 2017-07-31
HRP20170056T1 (hr) 2017-03-24
JP6169644B2 (ja) 2017-07-26
CZ29723U1 (cs) 2016-08-30
DK3199172T3 (en) 2018-10-08
PT2949335T (pt) 2017-02-03
SK501352015U1 (sk) 2017-07-03
EP2949335B1 (en) 2017-01-04
US20180185274A1 (en) 2018-07-05
EP3199172B1 (en) 2018-07-11
DK201600003Y3 (da) 2016-02-12
CZ30474U1 (cs) 2017-03-14
EP2949335A1 (en) 2015-12-02
EP3409286B1 (en) 2020-08-12
IL251943A0 (en) 2017-06-29
RS55607B1 (sr) 2017-06-30
SI2949335T1 (sl) 2017-05-31
EP2405749A1 (en) 2012-01-18
LT2949335T (lt) 2017-03-27
US8969302B2 (en) 2015-03-03
ME02662B (me) 2017-06-20
KR20120090044A (ko) 2012-08-16

Similar Documents

Publication Publication Date Title
RS52885B (sr) Niskofrekventna terapija glatiramer acetatom
AU2016100455A4 (en) Low frequency glatiramer acetate therapy
AU2015101563A4 (en) Low frequency glatiramer acetate therapy
HK1234325A1 (en) Dosing regimen for multiple sclerosis
HK1234325B (en) Dosing regimen for multiple sclerosis
HK1165959B (en) Low frequency glatiramer acetate therapy
HK1188722A (en) Low frequency glatiramer acetate therapy
HK1188722B (en) Low frequency glatiramer acetate therapy
HK1218250B (en) Low frequency glatiramer acetate therapy